Product Details
Place of Origin: China
Brand Name: Sunshine
Certification: ISO,COA
Model Number: 120410-24-4
Payment & Shipping Terms
Minimum Order Quantity: Negotiation
Price: Negotiation
Packaging Details: Aluminum Foil Bag, Drum
Delivery Time: 7-15DAY
Payment Terms: L/C,D/A,D/P,T/T,Western Union,MoneyGram
Supply Ability: G,KG,TON
Appearance:: |
White To Light Yellow Powder |
CAS NO:: |
120410-24-4 |
Molecular Formula:: |
C15H18N4O4S |
Molecular Weight:: |
350.39300 |
EINECS NO:: |
204-352-8 |
MDL NO:: |
MFCD00864863 |
Appearance:: |
White To Light Yellow Powder |
CAS NO:: |
120410-24-4 |
Molecular Formula:: |
C15H18N4O4S |
Molecular Weight:: |
350.39300 |
EINECS NO:: |
204-352-8 |
MDL NO:: |
MFCD00864863 |
Product Description:
Product Name: Biapenem CAS NO: 120410-24-4
Synonyms:
OMegacin;
BiapeneM Crude;
6-[[(4r,5s,6s)-2-carboxy-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]thio]-6,7-dihydro-5h-pyrazolo[1,2-a][1,2,4]triazol-4-ium inner salt;
Chemical & Physical Properties:
Appearance: White to light yellow powder
Assay :≥99.00%
Refractive Index: 1.651
Melting Point: 265-271℃ (dec.)
Solubility: H2O: ≥5mg/mL (warmed)
Storage Condition: -20℃ Freezer
Safety Information:
WGK Germany: 3
1. It is a kind of total synthesis gatifloxacin antibacterial drug.
2. Biapenem is a kind of carbapenem synthetic antibiotic. Its salt form is white or off-white powder. It is soluble in water, but insoluble in common organic solvents. It is more stable to the action of renal dehydropeptidase than meropenem and is not necessary to be combined with the enzyme inhibitor. It can fight against gram-negative bacteria, especially with a stronger antibacterial activity against Pseudomonas aeruginosa than imipenem; the antibacterial activity against aerobic Gram-positive bacteria is slightly lower than that of imipenem; its anti-anaerobe activity is the same as imipenem. Biapenem is a parenteral carbapenem antibacterial agent with a broad spectrum.Target: AntibacterialBiapenem is a carbapenem antibiotic of in vitro antibacterial activity encompassing many Gramnegative and Gram-positive aerobic and anaerobic bacteria, including species producing β-lactamases. Biapenem is more stable than imipenem, mero-penem and panipenem to hydrolysis by human renal dihydropeptidase-I (DHP-I), and therefore does not require the coadministration of a DHP-I inhibitor. In randomised, nonblind or double-blind clinical trials, biapenem showed good clinical and bacteriological efficacy (similar to that of imipenem/ cilastatin) in the treatment of adult patients with intra-abdominal infections, lower respiratory infections or complicated urinary tract infections.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.